AstraZeneca won U.S. approval of its Bydureon pen for once-weekly treatment of Type 2 diabetes. The pen will be the first of its kind to hit the market. The prefilled, single-use pen injector delivers microspheres that house exenatide, which is slowly released for better glycemic control.
On Tuesday morning, Medtronic reported that its third quarter net earnings sank to $762 million, taking a 23% hit due in large part to setbacks in its renal denervation program and tax changes affecting the med tech industry.
One in three people in the U.S. either already have or are at high risk of developing diabetes, and analyzing genetic data for answers about how best to treat these patients is a daunting task. Now a collection of Big Pharma companies are teaming up to share the burden.
Israel's Oramed touted results from a successful Phase IIa trial of its insulin pill, saying the oral Type 2 diabetes treatment is safe and well-tolerated. But since then, some analysts and media outlets have criticized the company for being less than forthcoming about the data.
Children as young as 2 years old can now use the latest in diabetes technology, even as the company that developed it is in a race to make it yesterday's news. The FDA announced Monday it has approved a pediatric version of DexCom's G4 Platinum. The San Diego med tech now has the first continuous glucose monitor (CGM) approved in the U.S. for toddlers.
Evoke Pharma showed in a recent study that its nasal spray for the delivery of a generic gastrointestinal drug performed better than the traditional oral form. The nasal delivery method could help patients take the drug when they are suffering from nausea and have difficulty swallowing a pill.
Following weeks of speculation about what a Google R&D team might have been doing at a December FDA meeting, the search-engine giant has confirmed that it's inventing a contact lens to help diabetes patients monitor their glucose levels. Google is now testing the lens, which measures glucose in tears with a miniaturized sensor and wireless chip.
Christopher Jones flew in from the U.K. to San Francisco on Jan. 10 to get a head start on celebrating milestones and networking. But the 2014 JPMorgan Healthcare Conference, which began on Jan. 13, was high on his agenda.
Since setting up shop in 2006, WellDoc has financed development of its mobile diabetes management tool through debt and angel investment, snagging itself the input of pharma veterans in the process. Now, it has landed its first round of institutional investment, with Merck Global Health Innovation Fund and others committing $20 million.
Fresh off a $25 million IPO, Evoke is riding into Phase III with its gastroparesis-treating nasal spray, and now the biotech has recruited SynteractHCR to serve as its go-to CRO for the late-stage effort.